ME02777B - Derivati hinazolina, lekovi koii sadrže ova jedinjenja, njihova primena i postupak za njihovo pripremanje - Google Patents
Derivati hinazolina, lekovi koii sadrže ova jedinjenja, njihova primena i postupak za njihovo pripremanjeInfo
- Publication number
- ME02777B ME02777B MEP-2008-595A MEP59508A ME02777B ME 02777 B ME02777 B ME 02777B ME P59508 A MEP59508 A ME P59508A ME 02777 B ME02777 B ME 02777B
- Authority
- ME
- Montenegro
- Prior art keywords
- amino
- buten
- oxo
- fluorophenyl
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 18
- 239000003814 drug Substances 0.000 title claims 4
- 238000000034 method Methods 0.000 title claims 3
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 201000010099 disease Diseases 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 210000004072 lung Anatomy 0.000 claims abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 106
- -1 1-phenylethyl- yl Chemical group 0.000 claims 91
- 125000001207 fluorophenyl group Chemical group 0.000 claims 5
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- BHEXDWNZKZGCJR-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N1=CN=C2C=C(OCC3CC3)C(NC(=O)C=CCN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 BHEXDWNZKZGCJR-UHFFFAOYSA-N 0.000 claims 2
- LZMNXUNFWRLHHN-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[methyl(oxan-4-yl)amino]but-2-enamide Chemical compound C1COCCC1N(C)CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 LZMNXUNFWRLHHN-UHFFFAOYSA-N 0.000 claims 2
- QTAWAYCWPSDGLD-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[methyl(oxolan-2-ylmethyl)amino]but-2-enamide Chemical compound C1CCOC1CN(C)CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 QTAWAYCWPSDGLD-UHFFFAOYSA-N 0.000 claims 2
- ZDNKZACCJCAFSG-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[methyl(oxolan-3-yl)amino]but-2-enamide Chemical compound C1COCC1N(C)CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 ZDNKZACCJCAFSG-UHFFFAOYSA-N 0.000 claims 2
- PQTDSJWQNYBZMA-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OCC1CC1)=C2NC(=O)C=CCN1CCOCC1 PQTDSJWQNYBZMA-UHFFFAOYSA-N 0.000 claims 2
- LFGWXNIIQPTINQ-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]-4-(diethylamino)but-2-enamide Chemical compound N1=CN=C2C=C(OC3CCC3)C(NC(=O)C=CCN(CC)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 LFGWXNIIQPTINQ-UHFFFAOYSA-N 0.000 claims 2
- YZPACYGAVMMGRL-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OC1CCC1)=C2NC(=O)C=CCN1CCOCC1 YZPACYGAVMMGRL-UHFFFAOYSA-N 0.000 claims 2
- XLQQWXQUVRKGRC-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OC1CCCC1)=C2NC(=O)C=CCN1CCOCC1 XLQQWXQUVRKGRC-UHFFFAOYSA-N 0.000 claims 2
- QXARYKFROPKLFO-HXUWFJFHSA-N n-[7-(cyclopropylmethoxy)-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-(diethylamino)but-2-enamide Chemical compound C1([C@@H](C)NC2=C3C=C(C(=CC3=NC=N2)OCC2CC2)NC(=O)C=CCN(CC)CC)=CC=CC=C1 QXARYKFROPKLFO-HXUWFJFHSA-N 0.000 claims 2
- SBXDXDHBBHYRGU-HXUWFJFHSA-N n-[7-(cyclopropylmethoxy)-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=CC=2NC(=O)C=CCN3CCOCC3)=NC=NC1=CC=2OCC1CC1 SBXDXDHBBHYRGU-HXUWFJFHSA-N 0.000 claims 2
- PATVDKNAXGUIID-HXUWFJFHSA-N n-[7-cyclobutyloxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-(diethylamino)but-2-enamide Chemical compound C1([C@@H](C)NC2=C3C=C(C(=CC3=NC=N2)OC2CCC2)NC(=O)C=CCN(CC)CC)=CC=CC=C1 PATVDKNAXGUIID-HXUWFJFHSA-N 0.000 claims 2
- BIIBDUPFBLCZKC-OAQYLSRUSA-N n-[7-cyclopentyloxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-(diethylamino)but-2-enamide Chemical compound C1([C@@H](C)NC2=C3C=C(C(=CC3=NC=N2)OC2CCCC2)NC(=O)C=CCN(CC)CC)=CC=CC=C1 BIIBDUPFBLCZKC-OAQYLSRUSA-N 0.000 claims 2
- ADOYXBQVLRRQGX-OAQYLSRUSA-N n-[7-cyclopentyloxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=CC=2NC(=O)C=CCN3CCOCC3)=NC=NC1=CC=2OC1CCCC1 ADOYXBQVLRRQGX-OAQYLSRUSA-N 0.000 claims 2
- VAJRZYCXBHKDQM-UHFFFAOYSA-N 2-(oxan-4-yloxy)quinazoline Chemical compound C1COCCC1OC1=NC=C(C=CC=C2)C2=N1 VAJRZYCXBHKDQM-UHFFFAOYSA-N 0.000 claims 1
- PKJIJECMPSQBNR-JTQLQIEISA-N 2-[(3s)-oxolan-3-yl]oxyquinazoline Chemical compound C1OCC[C@@H]1OC1=NC=C(C=CC=C2)C2=N1 PKJIJECMPSQBNR-JTQLQIEISA-N 0.000 claims 1
- BWYJJZBRYSADRP-UHFFFAOYSA-N 2-methoxyquinazoline Chemical compound C1=CC=CC2=NC(OC)=NC=C21 BWYJJZBRYSADRP-UHFFFAOYSA-N 0.000 claims 1
- KULGXJSSBLEZRX-UHFFFAOYSA-N 4-[bis(2-methoxyethyl)amino]-n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]but-2-enamide Chemical compound N1=CN=C2C=C(OCC3CC3)C(NC(=O)C=CCN(CCOC)CCOC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 KULGXJSSBLEZRX-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- ARFWPHOPKFABNZ-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-(diethylamino)but-2-enamide Chemical compound N1=CN=C2C=C(OCC3CC3)C(NC(=O)C=CCN(CC)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ARFWPHOPKFABNZ-UHFFFAOYSA-N 0.000 claims 1
- XBOPRYQUFUFBMU-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[ethyl(2-methoxyethyl)amino]but-2-enamide Chemical compound N1=CN=C2C=C(OCC3CC3)C(NC(=O)C=CCN(CCOC)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 XBOPRYQUFUFBMU-UHFFFAOYSA-N 0.000 claims 1
- FCOFHWKPTPGKHH-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(oxan-4-yloxy)quinazolin-6-yl]-4-[2-methoxyethyl(methyl)amino]but-2-enamide Chemical compound N1=CN=C2C=C(OC3CCOCC3)C(NC(=O)C=CCN(C)CCOC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 FCOFHWKPTPGKHH-UHFFFAOYSA-N 0.000 claims 1
- JPMHIEJCPJEURD-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(oxolan-2-ylmethoxy)quinazolin-6-yl]-4-(diethylamino)but-2-enamide Chemical compound N1=CN=C2C=C(OCC3OCCC3)C(NC(=O)C=CCN(CC)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 JPMHIEJCPJEURD-UHFFFAOYSA-N 0.000 claims 1
- QJDDCALYONSTKA-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(oxolan-2-ylmethoxy)quinazolin-6-yl]-4-[2-methoxyethyl(methyl)amino]but-2-enamide Chemical compound N1=CN=C2C=C(OCC3OCCC3)C(NC(=O)C=CCN(C)CCOC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 QJDDCALYONSTKA-UHFFFAOYSA-N 0.000 claims 1
- GEFDRSQXGUEZCT-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]-4-[2-methoxyethyl(methyl)amino]but-2-enamide Chemical compound N1=CN=C2C=C(OC3CCC3)C(NC(=O)C=CCN(C)CCOC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 GEFDRSQXGUEZCT-UHFFFAOYSA-N 0.000 claims 1
- VOJWMBYESNHOMY-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]-4-(diethylamino)but-2-enamide Chemical compound N1=CN=C2C=C(OC3CCCC3)C(NC(=O)C=CCN(CC)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 VOJWMBYESNHOMY-UHFFFAOYSA-N 0.000 claims 1
- UZXBYCKMQMBZKH-HXUWFJFHSA-N n-[7-cyclobutyloxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=CC=2NC(=O)C=CCN3CCOCC3)=NC=NC1=CC=2OC1CCC1 UZXBYCKMQMBZKH-HXUWFJFHSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10063435A DE10063435A1 (de) | 2000-12-20 | 2000-12-20 | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| PCT/EP2001/014569 WO2002050043A1 (de) | 2000-12-20 | 2001-12-12 | Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MEP59508A MEP59508A (en) | 2011-05-10 |
| ME02777B true ME02777B (me) | 2011-10-10 |
Family
ID=7667887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-595A ME02777B (me) | 2000-12-20 | 2001-12-12 | Derivati hinazolina, lekovi koii sadrže ova jedinjenja, njihova primena i postupak za njihovo pripremanje |
Country Status (39)
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200103692T2 (tr) | 1999-06-21 | 2002-10-21 | Boehringer Ingelheim Pharma Kg | Bisiklik heterosikilleri içeren ilaçlar ve üretimleri. |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| US20040044014A1 (en) | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| PE20040945A1 (es) * | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| DE10307165A1 (de) * | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10334226A1 (de) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| BRPI0414489A8 (pt) | 2003-09-16 | 2019-01-15 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina |
| US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE10349113A1 (de) * | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| EP1746999B1 (en) * | 2004-05-06 | 2011-11-16 | Warner-Lambert Company LLC | 4-phenylamino-quinazolin-6-yl-amides |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2006081741A1 (en) * | 2005-02-05 | 2006-08-10 | Piaoyang Sun | Quinazoline compounds or their medical salts and preparation and medical usage thereof |
| KR100832593B1 (ko) * | 2005-11-08 | 2008-05-27 | 한미약품 주식회사 | 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법 |
| EP2340837B1 (en) | 2005-11-11 | 2017-03-15 | Boehringer Ingelheim International GmbH | Combination treatment of cancer comprising egfr/her2 inhibitors |
| CA2629244C (en) | 2005-11-11 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| DK1981863T3 (da) | 2006-01-26 | 2013-01-02 | Boehringer Ingelheim Int | Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater |
| PT2068880E (pt) | 2006-09-18 | 2012-07-12 | Boehringer Ingelheim Int | Método para tratamento do cancro apresentando mutações no egfr |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
| EP2245026B1 (de) | 2008-02-07 | 2012-08-01 | Boehringer Ingelheim International GmbH | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| EP2303276B1 (en) | 2008-05-13 | 2013-11-13 | AstraZeneca AB | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline |
| PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| TWI385174B (zh) | 2008-11-10 | 2013-02-11 | Nat Health Research Institutes | 作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物 |
| US20120157472A1 (en) | 2009-01-14 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
| EP2647375A1 (en) | 2009-05-14 | 2013-10-09 | Boehringer Ingelheim International Gmbh | Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases |
| JP2012526767A (ja) * | 2009-05-14 | 2012-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌及び線維性疾患の処置における新規な併用療法 |
| WO2011003853A2 (en) | 2009-07-06 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
| EP2509592A1 (en) | 2009-12-07 | 2012-10-17 | Boehringer Ingelheim International GmbH | Bibw 2992 for use in the treatment of triple negative breast cancer |
| CN102686581B (zh) * | 2009-12-21 | 2015-08-26 | 张强 | 喹唑啉衍生物 |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| PT2608792T (pt) | 2010-08-26 | 2018-01-15 | Boehringer Ingelheim Int | Métodos de administração de um inibidor de egfr |
| CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| SG10201601711SA (en) | 2011-03-04 | 2016-04-28 | Newgen Therapeutics Inc | Alkyne Substituted Quinazoline Compound And Methods Of Use |
| CN102918029B (zh) | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| CN102838590B (zh) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| WO2013052157A1 (en) | 2011-10-06 | 2013-04-11 | Ratiopharm Gmbh | Crystalline forms of afatinib di-maleate |
| CN103073539B (zh) * | 2011-10-26 | 2016-05-11 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 |
| AR089727A1 (es) | 2012-01-17 | 2014-09-10 | Astellas Pharma Inc | Compuesto de pirazin-carboxamida |
| CN103772380A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| JP2016511754A (ja) | 2013-02-01 | 2016-04-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 放射性標識キナゾリン誘導体 |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303098A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HK1215378A1 (zh) | 2013-04-18 | 2016-08-26 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| CN103254182A (zh) * | 2013-05-10 | 2013-08-21 | 苏州明锐医药科技有限公司 | 一种阿法替尼的制备方法 |
| CN103254183B (zh) * | 2013-05-10 | 2015-11-11 | 苏州明锐医药科技有限公司 | 阿法替尼的制备方法 |
| WO2014180271A1 (zh) * | 2013-05-10 | 2014-11-13 | 苏州明锐医药科技有限公司 | 阿法替尼及其中间体的制备方法 |
| WO2014183560A1 (zh) * | 2013-05-16 | 2014-11-20 | 苏州明锐医药科技有限公司 | 阿法替尼及其中间体的制备方法 |
| CN103242303B (zh) * | 2013-05-16 | 2015-03-25 | 苏州明锐医药科技有限公司 | 阿法替尼的制备方法 |
| CN104513229A (zh) | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| CN103755688B (zh) * | 2013-12-24 | 2015-11-18 | 江苏奥赛康药业股份有限公司 | 一种阿法替尼化合物的制备方法 |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| WO2015103456A1 (en) | 2014-01-02 | 2015-07-09 | Teva Pharmaceuticals International Gmbh | Crystalline forms of afatinib di-maleate |
| CN105315263B (zh) * | 2014-07-30 | 2018-11-27 | 正大天晴药业集团股份有限公司 | 阿法替尼中间体的合成方法 |
| EP3023421A1 (en) | 2014-11-21 | 2016-05-25 | Sandoz Ag | Crystalline forms of afatinib dimaleate |
| CN105801568B (zh) | 2015-01-15 | 2019-07-30 | 杭州普晒医药科技有限公司 | 阿法替尼一马来酸盐晶型及其制备方法和药物组合物 |
| ES2775614T3 (es) * | 2015-03-20 | 2020-07-27 | Chai Tai Tianqing Pharmaceutical Group Co Ltd | Sales de derivado de quinazolina y método de preparación de las mismas |
| CN105175400B (zh) * | 2015-09-29 | 2018-04-10 | 河北神威药业有限公司 | 一种阿法替尼中间体的制备方法 |
| WO2017141271A1 (en) * | 2016-02-17 | 2017-08-24 | Sun Pharmaceutical Industries Ltd. | Stable pharmaceutical composition of afatinib |
| CN106442793B (zh) * | 2016-10-21 | 2019-05-24 | 河北神威药业有限公司 | 一种制备阿法替尼的中间体及其对映异构体的检测方法 |
| KR20250097990A (ko) | 2016-11-10 | 2025-06-30 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CA3085593A1 (en) | 2017-12-18 | 2019-06-27 | Sterngreene, Inc. | Pyrimidine compounds useful as tyrosine kinase inhibitors |
| CN110437163A (zh) * | 2018-05-03 | 2019-11-12 | 斯特恩格林公司 | 作为酪氨酸激酶抑制剂的嘧啶类化合物 |
| AU2019346550A1 (en) | 2018-09-25 | 2021-04-22 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
| CN109265449B (zh) * | 2018-11-07 | 2021-11-23 | 沈阳工业大学 | Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途 |
| BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
| CN109824657A (zh) * | 2019-03-26 | 2019-05-31 | 石药集团中奇制药技术（石家庄）有限公司 | 一种二马来酸阿法替尼新晶型及其制备方法和应用 |
| EP4013749A1 (en) | 2019-08-15 | 2022-06-22 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| CN110590682A (zh) * | 2019-10-14 | 2019-12-20 | 重庆医科大学 | 一种制备阿法替尼杂质的方法以及制备的杂质 |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN114980883A (zh) | 2020-01-20 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| TWI847289B (zh) * | 2021-09-30 | 2024-07-01 | 大陸商北京賽特明強醫藥科技有限公司 | 喹唑啉類化合物、組合物及其應用 |
| AU2023246862A1 (en) | 2022-03-31 | 2024-10-31 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| JP2025516171A (ja) | 2022-04-28 | 2025-05-27 | アストラゼネカ・アクチエボラーグ | 縮合二環式ヘテロ芳香族化合物及び癌の治療におけるその使用 |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| EP4543920A1 (en) | 2022-06-27 | 2025-04-30 | Astrazeneca AB | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1145614C (zh) * | 1996-04-12 | 2004-04-14 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物 |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| NZ513802A (en) * | 1999-02-27 | 2001-09-28 | Boehringer Ingelheim Pharma | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
| DE19911366A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19908567A1 (de) * | 1999-02-27 | 2000-08-31 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TR200103692T2 (tr) * | 1999-06-21 | 2002-10-21 | Boehringer Ingelheim Pharma Kg | Bisiklik heterosikilleri içeren ilaçlar ve üretimleri. |
| WO2001077104A1 (de) * | 2000-04-08 | 2001-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
-
2000
- 2000-12-20 DE DE10063435A patent/DE10063435A1/de not_active Withdrawn
-
2001
- 2001-12-12 DK DK01271363T patent/DK1345910T3/da active
- 2001-12-12 DE DE50114874T patent/DE50114874D1/de not_active Expired - Lifetime
- 2001-12-12 RS YUP-496/03A patent/RS50860B/sr unknown
- 2001-12-12 NZ NZ526918A patent/NZ526918A/en not_active IP Right Cessation
- 2001-12-12 EP EP09158964A patent/EP2112140A1/de not_active Withdrawn
- 2001-12-12 JP JP2002551540A patent/JP3827641B2/ja not_active Expired - Lifetime
- 2001-12-12 PT PT01271363T patent/PT1345910E/pt unknown
- 2001-12-12 EP EP01271363.2A patent/EP1345910B9/de not_active Expired - Lifetime
- 2001-12-12 IL IL15627701A patent/IL156277A0/xx unknown
- 2001-12-12 AT AT01271363T patent/ATE430136T1/de active
- 2001-12-12 SK SK771-2003A patent/SK287573B6/sk not_active IP Right Cessation
- 2001-12-12 BR BRPI0116266A patent/BRPI0116266B8/pt not_active IP Right Cessation
- 2001-12-12 AU AU1917402A patent/AU1917402A/xx active Pending
- 2001-12-12 SI SI200130916T patent/SI1345910T1/sl unknown
- 2001-12-12 UA UA2003076821A patent/UA74614C2/uk unknown
- 2001-12-12 CN CNB018208665A patent/CN1277822C/zh not_active Expired - Lifetime
- 2001-12-12 CA CA002432428A patent/CA2432428C/en not_active Expired - Lifetime
- 2001-12-12 EA EA200300671A patent/EA006317B1/ru not_active IP Right Cessation
- 2001-12-12 MX MXPA03005559A patent/MXPA03005559A/es active IP Right Grant
- 2001-12-12 KR KR1020037008246A patent/KR100852102B1/ko not_active Expired - Lifetime
- 2001-12-12 AU AU2002219174A patent/AU2002219174B2/en active Active
- 2001-12-12 HU HU0301852A patent/HU228874B1/hu active Protection Beyond IP Right Term
- 2001-12-12 ME MEP-2008-595A patent/ME02777B/me unknown
- 2001-12-12 HR HR20030504A patent/HRP20030504B1/xx not_active IP Right Cessation
- 2001-12-12 PL PL361798A patent/PL214798B1/pl unknown
- 2001-12-12 ES ES01271363T patent/ES2326617T3/es not_active Expired - Lifetime
- 2001-12-12 CZ CZ20031930A patent/CZ302721B6/cs not_active IP Right Cessation
- 2001-12-12 WO PCT/EP2001/014569 patent/WO2002050043A1/de not_active Ceased
- 2001-12-12 EE EEP200300300A patent/EE05244B1/xx active Protection Beyond IP Right Term
- 2001-12-17 UY UY27078A patent/UY27078A1/es not_active Application Discontinuation
- 2001-12-19 AR AR20010105883A patent/AR040524A1/es active IP Right Grant
- 2001-12-19 TW TW090131520A patent/TWI295992B/zh active
- 2001-12-19 MY MYPI20015767A patent/MY136086A/en unknown
-
2003
- 2003-05-28 ZA ZA200304141A patent/ZA200304141B/en unknown
- 2003-06-03 IL IL156277A patent/IL156277A/en active Protection Beyond IP Right Term
- 2003-06-16 NO NO20032726A patent/NO325672B1/no active Protection Beyond IP Right Term
- 2003-06-19 BG BG107929A patent/BG66139B1/bg unknown
-
2009
- 2009-07-23 CY CY20091100793T patent/CY1109290T1/el unknown
-
2014
- 2014-01-30 FR FR14C0009C patent/FR14C0009I2/fr active Active
- 2014-01-31 LU LU92370C patent/LU92370I2/fr unknown
- 2014-02-06 LT LTPA2014005C patent/LTC1345910I2/lt unknown
- 2014-02-11 NO NO2014003C patent/NO2014003I2/no not_active IP Right Cessation
- 2014-02-12 HU HUS1400005C patent/HUS1400005I1/hu unknown
- 2014-02-12 CY CY2014008C patent/CY2014008I2/el unknown
- 2014-02-18 BE BE2014C009C patent/BE2014C009I2/fr unknown
-
2022
- 2022-07-01 NO NO2022028C patent/NO2022028I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02777B (me) | Derivati hinazolina, lekovi koii sadrže ova jedinjenja, njihova primena i postupak za njihovo pripremanje | |
| JP2004516283A5 (cg-RX-API-DMAC7.html) | ||
| CA2196640C (en) | Substituted quinazoline derivatives | |
| ES2552813T3 (es) | Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparación | |
| MXPA97000883A (en) | Derivatives substituted from quinazol | |
| DE10042058A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
| JPH11504031A (ja) | キナゾリン誘導体 | |
| CN103965114B (zh) | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 | |
| DE10042062A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung | |
| WO2006034833A1 (en) | Cyclic diarly ureas suitable as tyrosine kinase inhibitors | |
| DE10042060A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
| CN102786481B (zh) | 厄洛替尼衍生物 | |
| CN102812010A (zh) | 喹唑啉衍生物及其制备方法和应用 | |
| CN118125997B (zh) | 紫檀芪丹皮酚查尔酮酰胺类衍生物、其制法及医药用途 | |
| JP7223684B2 (ja) | ピラゾロ［３，４－ｄ］ピリミジン化合物を用いた抗腫瘍効果増強剤 | |
| AU2008215053B2 (en) | The salts of 4-aniline quinazoline derivative | |
| CN106565684A (zh) | 6‑吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用 | |
| CN101679312B (zh) | 3,4-二氢喹唑啉衍生物 | |
| Yamaguchi-Sasaki et al. | Discovery of a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins through the modulation of atropisomer interconversion properties | |
| CN107903248B (zh) | N-取代靛红杂合喹唑啉类化合物合成的靛红衍生物及在制备抗肿瘤药物中的应用 | |
| CN118724907B (zh) | 一种大环多胺衍生的喹唑啉化合物及其制备方法与应用 | |
| CN115073442A (zh) | 含双硫键化合物、及其制法和药物组合物与用途 | |
| RU2799006C2 (ru) | СРЕДСТВО, УСИЛИВАЮЩЕЕ ПРОТИВООПУХОЛЕВОЕ ДЕЙСТВИЕ С ПРИМЕНЕНИЕМ СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-d]ПИРИМИДИНА | |
| CN110117275A (zh) | 一种氨基嘧啶类化合物及其在抗癌症药物中的应用 | |
| DE19928306A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |